Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. develops and commercializes drug-delivery technologies for subcutaneous administration of biologics and other injectable therapies. News about HALO commonly covers ENHANZE licensing agreements, Hypercon and Surf Bio hyperconcentration collaborations, partner product regulatory approvals, royalty-based revenue updates, and financial guidance.
The company also reports developments tied to its proprietary products Hylenex and XYOSTED, drug-device combination products using auto-injector technologies, and collaborations with pharmaceutical and biotechnology companies in oncology, inflammatory disease and other therapeutic areas.
Halozyme (NASDAQ: HALO) will report its fourth quarter and full year 2025 financial and operating results on Tuesday, February 17, 2026, released after the close of trading.
According to the company, a conference call to discuss results will be held on February 17, 2026 at 1:30pm PT / 4:30pm ET, with live webcast and replay available via Halozyme's Investors website.
Halozyme (Nasdaq: HALO) raised its outlook after strong 2025 momentum, updating preliminary 2025 revenue to $1,385–$1,400M (36–38% YoY) and royalty revenue to $865–$870M (51–52% YoY). For 2026 the company raised guidance to $1,710–$1,810M total revenue and $1,130–$1,170M royalties, with adjusted EBITDA of $1,125–$1,205M and non-GAAP EPS of $7.75–$8.25. Halozyme acquired Surf Bio for an upfront $300M (up to $400M total) to add hyperconcentration technology enabling formulations up to 500 mg/mL.
Nootropics Depot (HALO) corrected its Sept. 16, 2025 release to report that its High Potency Saffron Extract capsules are standardized to 7.5% crocins and 1% safranals, claiming the highest measured concentrations among tested supplements.
Independent and ISO‑accredited HPLC testing reportedly shows the product contains 1.97x more crocins and 1.18x more safranal per capsule versus the next competitor; manufacturing occurs in cGMP and FDA‑registered facilities in Arizona, with batch COAs publicly available.
Halozyme (NASDAQ: HALO) will host an investor conference call on Wednesday, January 28, 2026 at 5:30 AM PT / 8:30 AM ET. Management led by Dr. Helen Torley, President and CEO, and Nicole LaBrosse, CFO, will provide preliminary unaudited full-year 2025 revenue results, updated 2026–2028 financial guidance, and a business update. The call requires pre-registration and will be webcast live via the Investors section of Halozyme.com, with presentation materials available 15 minutes before the call and a recording posted after the call.
Halozyme (NASDAQ: HALO) announced a global collaboration and exclusive license agreement with Takeda (signed December 2025) to provide access to Halozyme's ENHANZE® rHuPH20 drug delivery technology for use with vedolizumab (marketed as ENTYVIO).
Under the agreement, Takeda will make an upfront payment to Halozyme, potential future development and commercial milestone payments, and Halozyme may receive up to low-mid single digit royalties on sales of vedolizumab combined with ENHANZE®. Vedolizumab is approved for IV and SC administration in various markets for adults with moderately to severely active Crohn's disease or ulcerative colitis.
Halozyme (NASDAQ: HALO) announced that the U.S. FDA approved RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) co-formulated with ENHANZE for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer on Dec 18, 2025. RYBREVANT FASPRO™ is approved across all RYBREVANT indications and is the first and only subcutaneous targeted therapy for EGFR+ mNSCLC.
Compared with IV delivery, administration time fell to ~5 minutes and administration-related reactions declined ~fivefold (13% SC vs 66% IV). The product met both co-primary PK endpoints in Phase 3 PALOMA-3 (Ctrough at C2D1 or C4D1 and C2 AUC D1-D15). Johnson & Johnson issued related press details on Dec 17, 2025.
Halozyme (NASDAQ: HALO) announced on December 8, 2025 that Jim Lang was elected to its Board of Directors. Mr. Lang brings over 30 years of executive experience in healthcare, life sciences, business services and data analytics.
His recent roles include CEO of EVERSANA, where he led growth through the acquisition of more than 20 companies and a merger with Waltz Health in August 2025, and former CEO of Decision Resources Group. Mr. Lang currently serves on the boards of Biovie and OptimizeRx and holds a B.S. in Electrical and Computer Engineering from the University of New Hampshire and an MBA from Tuck School of Business at Dartmouth.
Halozyme (NASDAQ: HALO) said a German court granted a preliminary injunction on Dec 4, 2025 ordering Merck to stop distributing and offering Keytruda SC in Germany for activity that would infringe European Patent No. 2 797 622 (EP 622) covering Halozyme's MDASE technology.
The order halts Merck's German launch activities within the injunction's scope; the decision is appealable and separate nullity proceedings filed by Merck in Aug 2025 are pending. Halozyme said Keytruda IV remains available and reiterated ongoing U.S. litigation alleging U.S. subcutaneous Keytruda (marketed as QLEX) infringes multiple MDASE patents.
Halozyme (NASDAQ: HALO) announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the 8th Annual Evercore Healthcare Conference. The presentation is scheduled for Tuesday, December 2, 2025 at 10:20 AM PT / 1:20 PM ET. A live audio webcast will be available on the company's Investor Relations website, and replays will be accessible for 90 days after the conference.
Halozyme (NASDAQ: HALO) completed its acquisition of Elektrofi, adding the Hypercon™ ultra‑high concentration microparticle formulation platform to its drug delivery portfolio.
Key terms: $750 million upfront, up to $900 million total with three $50 million regulatory milestones; company projects royalty revenue beginning in 2030 and up to $275 million in partner‑linked milestones from two programs expected to enter clinical development by year‑end 2026. Halozyme expects ~$55 million incremental operating expense in 2026 and estimates the deal will be less than 5% dilutive to non‑GAAP diluted EPS over the medium term.